The Proof with Simon Hill

Lowering cholesterol with medicine | Dr Thomas Dayspring and Dr Dan Soffer

78 snips
Sep 1, 2025
Dr. Thomas Dayspring, a lipidology expert, and Dr. Dan Soffer, a cardiologist specializing in preventive cardiology, dive into the world of lipid-lowering therapies. They discuss the effectiveness of statins, ezetimibe, and newer drugs like bempedoic acid. The conversation highlights who benefits most from these treatments and the importance of personalized care. Historical clinical trials radically transformed our understanding of cholesterol management, revealing how early intervention can significantly reduce cardiovascular risk. They also touch on the challenges of including women in clinical trials.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

Shared Final Pathway For LDL Lowering

  • Different drug classes (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) all lower LDL by increasing liver LDL-receptor activity.
  • The final common effect is improved clearance of ApoB-containing particles, reducing atherosclerotic risk.
ADVICE

Consider Lowering LDL Earlier

  • Don’t rely only on 10-year risk calculators; consider lifelong exposure and earlier intervention for high lifetime LDL.
  • Use clinician judgment to start therapy earlier in people with biomarkers, imaging, or family history suggesting high risk.
ADVICE

Offer Statins After Shared Decision In Low-Risk Young Adults

  • If a low-risk 30-year-old with LDL ~125–130 wants to start therapy, clinicians can reasonably offer a statin (± ezetimibe) after shared decision-making.
  • Guidelines don't forbid treating lower-risk people, so personalize based on preferences and lifetime risk.
Get the Snipd Podcast app to discover more snips from this episode
Get the app